Patents by Inventor Kavon Rezai-Zadeh

Kavon Rezai-Zadeh has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8802638
    Abstract: The flavonoid luteolin reduces amyloid-? peptide (A?) generation. Luteolin is also a selective GSK-3 inhibitor that 1) decreases amyloidogenic ?-secretase APP processing, and 2) promotes presenilin 1 (PS1) carboxyl-terminal fragment (CTF) phosphorylation. GSK-3? activity is essential for both PS1 CTF phosphorylation states and PS1-APP interaction. These findings were validated in vivo, using a Tg2576 Alzheimer's Disease model system. Luteolin treatment decreased soluble A? levels, reduced GSK-3 activity, and disrupted PS1-APP association. In addition, Tg2576 mice treated with diosmin, a glycoside of a flavone structurally and functionally similar to luteolin (diosmetin), displayed significantly reduced A? pathology as well.
    Type: Grant
    Filed: April 9, 2009
    Date of Patent: August 12, 2014
    Assignee: University of South Florida
    Inventors: Jun Tan, Doug Shytle, Kavon Rezai-Zadeh
  • Patent number: 8778986
    Abstract: The bioflavonoid luteolin reduces amyloid-? peptide (A?) generation. Luteolin is also a selective GSK-3 inhibitor that 1) decreases amyloidogenic ?-secretase APP processing, and 2) promotes presenilin-1 (PS1) carboxyl-terminal fragment (CTF) phosphorylation. GSK-3? activity is essential for both PS1 CTF phosphorylation states and PS1-APP interaction. To validate The findings were validated in vivo, using a Tg2576 Alzheimer's Disease model system. Luteolin treatment decreased soluble A? levels, reduced GSK-3 activity, and disrupted PS1-APP association.
    Type: Grant
    Filed: January 25, 2008
    Date of Patent: July 15, 2014
    Assignee: University of South Florida
    Inventors: Jun Tan, Doug Shytle, Kavon Rezai-Zadeh